Neurobiology and Pain Therapeutics Section, Laboratory of Sensory Biology, National Institute of Dental and Craniofacial Research, Clinical Center, National Institutes of Health, Bethesda, Maryland, USA.
J Infect Dis. 2010 Jun 15;201(12):1919-22. doi: 10.1086/652869.
Antibody responses against lytic and latent Kaposi sarcoma (KS)-associated herpesvirus antigens were investigated in patients with KS, multicentric Castleman disease (MCD), and primary effusion lymphoma. Antibodies against the lytic antigen K8.1 were 5-fold higher in patients with MCD than those with KS, whereas antibodies to the sum of latent antigens v-cyclin and LANA were 27-fold higher in patients with KS, compared with patients with MCD (P < 001). The sum of anti-v-cyclin and anti-LANA antibody titers discriminated patients with KS from those with MCD and KS with 93% sensitivity and 83% specificity. These results suggest that antibody responses to lytic and latent KS-associated herpesvirus antigens differ in these diseases.
检测了卡波济肉瘤(KS)、多中心 Castleman 病(MCD)和原发性渗出性淋巴瘤患者针对裂解和潜伏 Kaposi 肉瘤(KS)相关疱疹病毒抗原的抗体反应。与 KS 患者相比,MCD 患者的裂解抗原 K8.1 抗体高 5 倍,而 KS 患者的潜伏抗原 v-细胞周期蛋白和 LANA 的总和抗体比 MCD 患者高 27 倍(P<001)。抗 v-细胞周期蛋白和抗 LANA 抗体滴度总和可区分 KS 患者、MCD 患者和 KS 患者,其敏感性为 93%,特异性为 83%。这些结果表明,这些疾病中针对裂解和潜伏 KS 相关疱疹病毒抗原的抗体反应不同。